Nuvalent offers $300M in stock after a second cancer drug shows promise


Nuvalent Inc. is holding a $300 million stock offering just days after it presented promising data from its second lead cancer drug.

Previous CVS Health Corp. CFO Shawn Guertin takes leave of absence
Next West Allis mayor tells Burger King 'I rule' as city sues over 'blighted' restaurant site